Exelixis Reports 'Encouraging' Data in Kidney Cancer Trial

MT Newswires Live

May 23, 2025

Exelixis (EXEL) said late Thursday preliminary results from an expansion cohort of a phase 1b/2 study in advanced kidney cancer showed an objective response rate of 63% and a disease control rate of 90%.

The trial was evaluating zanzalintinib in combination with either nivolumab or a fixed-dose combination of nivolumab and relatlimab in patients with previously untreated advanced clear cell renal cell carcinoma, the company said.

"We are pleased to present these preliminary findings from the...study, including early signs of promising activity for zanzalintinib in combination with immune checkpoint inhibitors," said Chief Medical Officer Amy Peterson.

The findings will be presented at the American Society of Clinical Oncology annual meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2537920024"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537920024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537920024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 06:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537920024","market":"hk","top_or_hot":-1,"title":"Exelixis Reports 'Encouraging' Data in Kidney Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Exelixis (EXEL) said late Thursday preliminary results from an expansion cohort of a phase 1b/2 study in advanced kidney cancer showed an objective response rate of 63% and a disease control rate of 90%.</p><p>The trial was evaluating zanzalintinib in combination with either nivolumab or a fixed-dose combination of nivolumab and relatlimab in patients with previously untreated advanced clear cell renal cell carcinoma, the company said.</p><p>\"We are pleased to present these preliminary findings from the...study, including early signs of promising activity for zanzalintinib in combination with immune checkpoint inhibitors,\" said Chief Medical Officer Amy Peterson.</p><p>The findings will be presented at the American Society of Clinical Oncology annual meeting.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exelixis Reports 'Encouraging' Data in Kidney Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExelixis Reports 'Encouraging' Data in Kidney Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-23 06:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Exelixis (EXEL) said late Thursday preliminary results from an expansion cohort of a phase 1b/2 study in advanced kidney cancer showed an objective response rate of 63% and a disease control rate of 90%.</p><p>The trial was evaluating zanzalintinib in combination with either nivolumab or a fixed-dose combination of nivolumab and relatlimab in patients with previously untreated advanced clear cell renal cell carcinoma, the company said.</p><p>\"We are pleased to present these preliminary findings from the...study, including early signs of promising activity for zanzalintinib in combination with immune checkpoint inhibitors,\" said Chief Medical Officer Amy Peterson.</p><p>The findings will be presented at the American Society of Clinical Oncology annual meeting.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXEL","symbol_name":"伊克力西斯","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2537920024","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537920024","pubTimestamp":1747951330,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Exelixis  said late Thursday preliminary results from an expansion cohort of a phase 1b/2 study in advanced kidney cancer showed an objective response rate of 63% and a disease control rate of 90%.The trial was evaluating zanzalintinib in combination with either nivolumab or a fixed-dose combination of nivolumab and relatlimab in patients with previously untreated advanced clear cell renal cell carcinoma, the company said.\"We are pleased to present these preliminary findings from the...study, including early signs of promising activity for zanzalintinib in combination with immune checkpoint inhibitors,\" said Chief Medical Officer Amy Peterson.The findings will be presented at the American Society of Clinical Oncology annual meeting.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXEL":"伊克力西斯","BK4532":"文艺复兴科技持仓","BK4139":"生物科技"},"translate_title":"Exelixis报告肾癌试验数据“令人鼓舞”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1},"content_text":"Exelixis (EXEL) said late Thursday preliminary results from an expansion cohort of a phase 1b/2 study in advanced kidney cancer showed an objective response rate of 63% and a disease control rate of 90%.The trial was evaluating zanzalintinib in combination with either nivolumab or a fixed-dose combination of nivolumab and relatlimab in patients with previously untreated advanced clear cell renal cell carcinoma, the company said.\"We are pleased to present these preliminary findings from the...study, including early signs of promising activity for zanzalintinib in combination with immune checkpoint inhibitors,\" said Chief Medical Officer Amy Peterson.The findings will be presented at the American Society of Clinical Oncology annual meeting.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}